AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.
The drug is intended to be administered using a small, portable infusion pump, which delivers carbidopa and levodopa directly into the small intestine for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?